Comparative Pharmacology
Head-to-head clinical analysis: OPHTHOCORT versus PREDSULFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPHTHOCORT versus PREDSULFAIR.
OPHTHOCORT vs PREDSULFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
PREDSULFAIR is a combination of prednisolone (corticosteroid) and sulfacetamide (sulfonamide antibiotic). Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
Prednisolone 0.5-1 mg/kg orally once daily, maximum 60 mg/day; Sulfasalazine 500 mg orally twice daily, increased by 500 mg weekly to maintenance 2-3 g/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Prednisolone: 2.1–3.5 hours (plasma); biological half-life 12–36 hours (duration of HPA axis suppression). Sulfafurazole: 3–6 hours (normal renal function), prolonged to 12–24 hours in renal impairment.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
PREDSULFAIR is a fixed-dose combination of prednisolone and sulfafurazole. Prednisolone is primarily metabolized hepatically; inactive metabolites are excreted renally (<30% unchanged). Sulfafurazole is acetylated and glucuronidated; parent drug and metabolites are excreted renally (≥90%, with 15-30% unchanged). Biliary/fecal elimination is minimal for both components (<5%).
Category C
Category C
Ophthalmic Corticosteroid/Antibiotic Combination
Ophthalmic Corticosteroid/Sulfonamide Combination